Eye and corticosteroid's use;Indications et complications des corticoïdes en ophtalmologie

Presse Medicale

Volumn 41, Issue 4, 2012, Pages 414-421

  Fel, Audrey ^a   Aslangul, Elisabeth ^a   Le Jeunne, Claire ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYPOTONIC SOLUTION;

ANTERIOR EYE SEGMENT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; EYE DISEASE; EYE EXAMINATION; EYE INFLAMMATION; GLAUCOMA; HUMAN; LONG TERM CARE; POSTERIOR EYE SEGMENT; PRESCRIPTION; RISK ASSESSMENT; RISK FACTOR; SCLERA; SHORT SURVEY; SUBCAPSULAR CATARACT; TREATMENT DURATION;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CATARACT; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPHTHALMITIS; GLAUCOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; RISK FACTORS;

EID: 84858754006     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.02.001     Document Type: Short Survey

References (35)

1. Sundmark E. The occurrence of posterior subcapsular cataracts in patients on long-term systemic corticosteroid therapy. Acta Ophthalmol (Copenh) 1963, 41:515-523.
2. Demailly PJBJ.P. La cataracte cortisonique. Œil et cortisone 1975, Masson, Paris.
3. Skalka H., Prchal J. Effect of corticosteroïds on cataract formation. Arch Ophtalmol 1980, 10:1773-1777.
4. Albert K., Sennesael J., Haentjens P. Incidence and risk factors for posttransplant subcapsular cataract: a long-term retrospective cohort study. Transplant Proc 2011, 43:3465-3469.
5. Krause I., Snir M., Cleper R., Fraser A., Kovalski Y., Axer Siegel R., et al. Ocular complications in children and adolescents following renal transplantation. Pediatr Transplant 2010, 14:77-81.
6. Nakamura T., Sasaki H., Nagai K., Fujisawa K., Sasaki K., Suzuki K., et al. Influence of cyclosporin on steroid-induced cataracts after renal transplantation. Jpn J Ophthalmol 2003, 47:254-259.
7. Weatherall M., James K., Clay J., Perrin K., Masoli M., Wijesinghe M., et al. Dose-response relationship for risk of non-vertebral fracture with inhaled corticosteroids. Clin Exp Allergy 2008, 38:1451-1458.
8. Emin O., Fatih M., Mustafa O., Nedim S., Osman C. Evaluation impact of long-term usage of inhaled fluticasone propionate on ocular functions in children with asthma. Steroids 2011, 76:548-552.
9. Gawchik S.M., Saccar C.L. A risk-benefit assessment of intranasal triamcinolone acetonide in allergic rhinitis. Drug Saf 2000, 23:309-322.
10. Derby L., Maier W.C. Risk of cataract among users of intranasal corticosteroids. J Allergy Clin Immunol 2000, 105:912-916.
11. Liu A., Manche E.E. Bilateral posterior subcapsular cataracts associated with long-term intranasal steroid use. J Cataract Refract Surg 2011, 37:1555-1558.
12. James E.R. The etiology of steroid cataract. J Ocul Pharmacol Ther 2007, 23:403-420.
13. Mohan R., Muralidharan A.R. Steroid induced glaucoma and cataract. Indian J Ophthalmol 1989, 37:13-16.
14. Jobling A.I., Augusteyn R.C. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataracts. Clin Exp Optom 2002, 85:61-75.
15. Kojima M., Shui Y.B., Murano H., Sasaki K. Inhibition of steroid-induced cataract in rat eyes by administration of vitamin-E ophthalmic solution. Ophthalmic Res 1996, 28(Suppl. 2):64-71.
16. Praveen M.R., Shah G.D., Vasavada A.R., Shah A.R., Johar K., Gami Y., et al. Posterior capsule opacification in eyes with steroid-induced cataracts: Comparison of early results. J Cataract Refract Surg 2011, 37:88-96.
17. Afssaps. Antibioprophylaxie en chirurgie oculaire, mai 2011, . http://www.afssaps.fr/.
18. El Afrit M.A., Mazlout H., Trojet S., Larguech L., Megaieth K., Belhaj S., et al. Glaucome cortisonique : étude épidémiologique, clinique et thérapeutique. J Fr Ophtalmol 2007, 30:49-52.
19. Matsumoto T., mori K., Kinoshita S., Johnson D. Dexamethasone increases the volume and DNA content of the nucleus in human trabecular meshwork cells. Invest Ophtalmol Vis Sci 1998, 39.
20. Porubska M., Krchnava B., Slamova J., Cepilova Z. Ophthalmic complications in general corticoid therapy. Cesk Oftalmol 1991, 47:281-285.
21. Garbe E., LeLorier J., Boivin J.F., Suissa S. Risk of ocular hypertension or open-angle glaucoma in elderly patients on oral glucocorticoids. Lancet 1997, 350:979-982.
22. Espidora C.V.C.D.B. Glaucome cortisonique : à propos de 44 yeux. J Fr Ophtalmol 1981, 4:503-508.
23. Trong D.P. Glaucome cortisonique : analyses clinique et physiopathologique, étude rétrospective des hypertonies cortico-induites 1996, Université Louis Pasteur, Strasbourg.
24. Jones R., Rhee D.J. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006, 17:163-167.
25. Primus S., Harris A., Siesky B.A., Guidoboni G. Diabetes: a risk factor for glaucoma?. Br J Ophthalmol 2011, 95(12):1621-1622.
26. Haimovici R., Koh S., Gagnon D.R., Lehrfeld T., Wellik S. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004, 111:244-249.
27. Hamard H. Corticoïdes et cicatrisation cornéenne. Œil et cortisone 1975, Masson, Paris.
28. Borderie V. Les greffes en ophtalmologie 2004, Elsevier, Paris.
29. Bodaghi B., Lehoang P. Uveite 2009, Elsevier, Paris.
30. Offret H., Labetoulle M., Frau E. Thérapeutiques en ophtalmologie 2003, Masson, Paris.
31. Cochereau I. Biodisponibilité des anti-inflammatoires. J Fr Ophtalmol 2000, 23:514-517.
32. Feldman-Billard S., Heron E. Tolérance systémique des corticoïdes en ophtalmologie : influence de la voie d'administration. J Fr Ophtalmol 2008, 31:1026-1036.
33. Bodaghi B. Uveite. Paris; 2009.
34. Korobelnik J., Cochereau I., Cohen S., Creuzot-Garcher C., Devin F., Gaudric A., et al. Description des pratiques pour la réalisation des injections intra vitréennes. J Fr Ophtalmol 2006, 29:82-86.
35. Went C.V., Offret H., Labetoulle M. Iatrogénie oculaire. Thérapeutiques 2008, 4:14-17.